Summary
Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2016’, provides an overview of the Venous Leg Ulcers (Crural ulcer) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
- The report reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Venous Leg Ulcers (Crural ulcer) therapeutics and enlists all their major and minor projects
- The report assesses Venous Leg Ulcers (Crural ulcer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adocia
CardioVascular BioTherapeutics, Inc.
CytoTools AG
FirstString Research, Inc.
MacroCure Ltd.
MediWound Ltd.
Pergamum AB
RegeneRx Biopharmaceuticals, Inc.
Stratatech Corporation
Tissue Therapies Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Leg Ulcers (Crural ulcer) Overview 7
Therapeutics Development 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview 8
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies 9
Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies 13
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development 14
Adocia 14
CardioVascular BioTherapeutics, Inc. 15
CytoTools AG 16
FirstString Research, Inc. 17
MacroCure Ltd. 18
MediWound Ltd. 19
Pergamum AB 20
RegeneRx Biopharmaceuticals, Inc. 21
Stratatech Corporation 22
Tissue Therapies Limited 23
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Biochaperone PDGF-BB - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural ulcer - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CL-05 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CODA-001 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CureXcell - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CVBT-141B - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
EscharEx - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Granexin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LL-37 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RGN-137 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VF-001 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Venous Leg Ulcers (Crural ulcer) - Recent Pipeline Updates 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects 59
Venous Leg Ulcers (Crural ulcer) - Discontinued Products 60
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones 61
Featured News & Press Releases 61
Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 61
Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers 62
Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment 62
Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results 62
Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications 63
May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication 64
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 64
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 65
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2016 14
Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016 15
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2016 16
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H1 2016 17
Venous Leg Ulcers (Crural ulcer) - Pipeline by MacroCure Ltd., H1 2016 18
Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd., H1 2016 19
Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H1 2016 20
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 21
Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corporation, H1 2016 22
Venous Leg Ulcers (Crural ulcer) - Pipeline by Tissue Therapies Limited, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Venous Leg Ulcers (Crural ulcer) Therapeutics - Recent Pipeline Updates, H1 2016 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2016 59
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2016 60
List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Targets, H1 2016 25
Number of Products by Stage and Targets, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 27
Number of Products by Stage and Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
